Navigation Links
Department of Energy Grants BlueFire Approval for Site Change
Date:10/15/2009

IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world's transportation fuel paradigm through the production of ethanol from non-food cellulosic wastes, has announced the strategic relocation of its second planned biorefinery to Fulton, Mississippi.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090511/BLUEFIRELOGO )

After having been awarded a $40 million dollar grant from the U.S. Department of Energy (DOE) for a second planned facility in California, BlueFire Ethanol, in 2007, began development and licensing work to build their second biorefinery plant.

"Navigating the development and licensing process in California in a time effective manner coupled with the challenging business climate in the State convinced BlueFire to petition the DOE for a site change to Mississippi," stated Arnold Klann, BlueFire's President and CEO. "We determined the Fulton site located in north eastern Mississippi was best suited to fulfill our requirements for our second biorefinery plant after studying various locations in several states over the past year."

"The DOE has been supportive and helpful in BlueFire's project development activities targeted at fulfilling the current administration's goal of rapid deployment of cellulosic biofuel projects. DOE's approval of the site change should help BlueFire remain on track for executing our business growth strategy," added Mr. Klann.

The Fulton, MS project will allow BlueFire to utilize green and wood wastes available in the region as feedstock for the ethanol plant that will be designed to produce approximately 18 million gallons of ethanol per year. BlueFire is currently receiving funding under the $40 million DOE grant it was awarded in 2007 for the development of the plant in Fulton, Mississippi.

BlueFire has completed a 20-month licensing process and is currently awaiting the final financing needed to break ground on its shovel-ready, fully permitted ethanol biorefinery in Lancaster, CA. The Lancaster facility will use post-sorted cellulosic wastes diverted from Southern California's landfills to produce approximately 3.9 million gallons of fuel-grade ethanol per year.

About BlueFire Ethanol Fuels

BlueFire Ethanol Fuels, Inc. was established to deploy a commercially ready, patented and proven Concentrated Acid Hydrolysis Technology Process for the profitable conversion of cellulosic waste materials ("Green Waste") to ethanol, a viable alternative to gasoline. BlueFire is the only cellulose-to-ethanol company worldwide with demonstrated production of ethanol from urban trash (post-sorted MSW), rice and wheat straws, wood waste and other agricultural residues.

BlueFire is one of four ethanol companies awarded funding from the U.S. Department of Energy to construct ethanol production facilities. Unlike remote corn ethanol production plants, BlueFire's biorefineries will be located near markets with high demand for ethanol. This should dramatically reduce delivery costs and increase biofuel supplies, while providing a unique waste processing technology to help America's cities better manage the increasing problem of overflowing landfills. For more information, please visit www.BlueFireEthanol.com.

Forward-Looking Statements

Statements about BlueFire Ethanol, Inc.'s expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. BlueFire's actual results could differ materially from expected results. BlueFire undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this press release; BlueFire will appropriately inform the public.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). BlueFire Ethanol, Inc. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful development and deployment of ethanol production facility or facilities, impact of the company's expansion plan, and new business development success, future financial results, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new facilities and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and BlueFire Ethanol, Inc. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE BlueFire Ethanol Fuels, Inc.


'/>"/>
SOURCE BlueFire Ethanol Fuels, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
2. Second U.S.-Egypt Collaborative Clinical Study Blocked by New York State Department of Health (NYSDOH), This Time on Complications of Diabetes
3. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
4. ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
5. Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer
6. FSU scientific computing department hosts international conference
7. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
8. Department of Justice Provides States With Funding for Testing in Postconviction Cases
9. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
10. Workforce Alliance Receives U.S. Labor Departments Excellence Award
11. U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)...  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company ... autoimmune diseases, asthma and allergic diseases and cancer, ... and full year ended December 31, 2016 and ... and clinical highlights. "During 2016, we ... by starting five clinical trials across our XmAb ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small cuvette manufacturer ... late 2014, FFS had a mission to bring affordable and quality lab equipment to ... product that gives a lab everything needed to get started with using cuvettes. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation ... Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. ... drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen ... from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. ... to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):